International Clinical Trials And Dealmaking – A One-Way Street Or Exchange Of Opportunity?

Ballard Spahr LLP—an Am Law 100 law firm with more than 750 lawyers in 18 U.S. offices—serves clients across industries in litigation, transactions, and regulatory compliance. A strategic legal partner to clients, Ballard goes beyond to deliver actionable, forward-thinking counsel and advocacy powered by deep industry experience and an understanding of each client’s specific business goals. Our culture is defined by an entrepreneurial spirit, collaborative environment, and top-down focus on service, efficiency, and results.

Explore Firm Details

Ryan Udell will moderate a discussion between Chong Xu of F-Prime Capital and Hugh Davis of Aclaris Therapeutics at Life Sciences PA's annual meeting.

United States

Ryan Udell, co-leader of Ballard Spahr's Life Sciences Industry Team, will speak at Life Sciences PA's annual Life Sciences Future meeting. Ryan will be moderating a conversation between Chong Xu, Partner at F-Prime Capital, and Hugh Davis, Ph.D., Chief Operating Officer and President of Aclaris Therapeutics, Inc.

The event description:

Clinical research and deals are increasingly crossing borders, creating new opportunities and challenges for the life sciences industry. This panel will explore the benefits, tradeoffs, and lessons learned from conducting global clinical trials. Hear perspectives from large and emerging biopharma companies and policymakers as they discuss how international clinical research and dealmaking are driving innovation, improving efficiencies, and shaping the future of drug development.

Event Details

October 2026

9:00 PM - 10:00 PM PST

The Sheraton Valley Forge
480 N Gulph Road

King of Prussia , PA 19406

Register Here

Contributor

Explore Firm Details

See More Popular Content From